| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/02/2000 | CN1243440A Dosage forms and method for ameliorating male erectile dysfunction |
| 02/02/2000 | CN1243436A New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof |
| 02/02/2000 | CN1243431A 皮肤制剂 Skin Product |
| 02/01/2000 | US6020478 Human tumor-associated antigen |
| 02/01/2000 | US6020383 Administering tert-butylhydroquinone |
| 02/01/2000 | US6020365 Anticancer agents; antitumor agents |
| 02/01/2000 | US6020356 Pharmaceutical composition for the treatment of autoimmune diseases |
| 02/01/2000 | US6020352 Treatment of ischemic disorders of the retina and optic nerve head |
| 02/01/2000 | US6020322 Acyl deoxyribonucleoside derivatives and uses thereof |
| 02/01/2000 | US6020321 Adenosine receptor agonists for the promotion of wound healing |
| 02/01/2000 | US6020320 Acyl deoxyribonucleoside derivatives and uses thereof |
| 02/01/2000 | US6020310 Method for assisting in differential diagnosis and treatment of autistic syndromes |
| 02/01/2000 | US6020308 Methods for improving therapeutic effectiveness of treatment of vascularization disorders |
| 02/01/2000 | US6020197 Neuroblasts are dependant upon about 1 to 100 ng/ml of bfgf for long term maintenance. |
| 02/01/2000 | US6020193 Recombinant C-proteinase and processes, methods and uses thereof |
| 02/01/2000 | US6020189 Fibroblast growth factor homologous factors (FHFs) and methods of use |
| 02/01/2000 | US6020179 Nucleic acids encoding human tyrosine phosphatases |
| 02/01/2000 | US6020165 Cytikine signal regulators |
| 02/01/2000 | US6020164 Human RNA binding proteins |
| 02/01/2000 | US6020161 PIGR-1, a member of immunoglobulin gene superfamily |
| 02/01/2000 | US6020157 Polynucleotides encoding HFGAN72X receptor |
| 02/01/2000 | US6020144 These organisms have evolved a sophisticated ability to infect a host and evade their host's immune defenses. |
| 02/01/2000 | US6020142 Rath genes and polypeptides and methods for the treatment and diagnosis of immune disorders |
| 02/01/2000 | US6020139 S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| 02/01/2000 | US6019979 Anti-viral treatment with pertussis toxin B oligomer |
| 02/01/2000 | US6019967 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin |
| 02/01/2000 | CA2163348C Calanolide and related antiviral compounds, compositions, and uses thereof |
| 01/27/2000 | WO2000004194A1 Gene sequence variances with utility in determining the treatment of disease |
| 01/27/2000 | WO2000004157A2 Cloning and characterisation of novel mammalian peptidases |
| 01/27/2000 | WO2000004150A1 Human presenilin-associated protein |
| 01/27/2000 | WO2000004137A1 Human aspartic proteases |
| 01/27/2000 | WO2000004050A2 Neurotrophic growth factor |
| 01/27/2000 | WO2000004045A1 Axor10, a g-protein coupled receptor |
| 01/27/2000 | WO2000004031A1 Phosphorous organic compounds and their use |
| 01/27/2000 | WO2000003749A2 Method for regulating hair growth |
| 01/27/2000 | WO2000003746A2 Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
| 01/27/2000 | WO2000003743A2 Use of inhibitors of prenyltransferases for inhibiting fungal growth |
| 01/27/2000 | WO2000003741A2 Methods for reducing intraocular pressure using a3-adenosine antagonists |
| 01/27/2000 | WO2000003737A2 Water-soluble drugs and methods for their production |
| 01/27/2000 | WO2000003721A1 Immunosupportive drug sparing diet |
| 01/27/2000 | WO2000003716A1 Topical compositions comprising an opioid analgesic and an nmda antagonist |
| 01/27/2000 | WO2000003715A1 Treatment of dyskinesia |
| 01/27/2000 | WO2000003713A1 Treatment for schizophrenia and other dopamine system dysfunctions |
| 01/27/2000 | WO2000003706A1 Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents |
| 01/27/2000 | WO2000003701A1 Composition for treatment of stress |
| 01/27/2000 | WO2000003700A1 Compositions and methods of treating abnormal cell proliferation |
| 01/27/2000 | WO2000003691A1 Systems and methods for local delivery of an agent |
| 01/27/2000 | WO1999063938A3 Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs |
| 01/27/2000 | WO1999063930A3 Novel angiotensin receptor modulators and their uses |
| 01/27/2000 | WO1999063115A3 Use of cathepsin s in the diagnosis and treatment of endometriosis |
| 01/27/2000 | WO1999061059A8 Minoxidil compositions for external use |
| 01/27/2000 | WO1999061008A3 Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals |
| 01/27/2000 | WO1999060127A3 Il-17 homologous polypeptides and therapeutic uses thereof |
| 01/27/2000 | DE19832519A1 Topical antiviral medicament for treating herpes infections, containing synergistic combination of adenosine and protein inhibiting antiviral agent, e.g. acyclovir |
| 01/27/2000 | CA2337883A1 Method for regulating hair growth |
| 01/27/2000 | CA2337507A1 Composition for treatment of stress |
| 01/27/2000 | CA2337499A1 Methods for reducing intraocular pressure using a3-adenosine antagonists |
| 01/27/2000 | CA2337362A1 Cloning and characterisation of novel mammalian peptidases |
| 01/27/2000 | CA2337179A1 Therapeutic composition based on flavonoids, intended to be used in the treatment of tomours by cytotoxic |
| 01/27/2000 | CA2337138A1 Compositions and methods of treating abnormal cell proliferation |
| 01/27/2000 | CA2336143A1 Aminoalkylphosphonic acid derivatives and their use in treating infections |
| 01/27/2000 | CA2335649A1 Gene sequence variances with utility in determining the treatment of disease |
| 01/27/2000 | CA2335381A1 Use of inhibitors of prenyltransferases for inhibiting fungal growth |
| 01/27/2000 | CA2333910A1 Neurotrophic growth factor |
| 01/27/2000 | CA2333467A1 Human presenilin-associated protein |
| 01/27/2000 | CA2303062A1 Human aspartic proteases |
| 01/26/2000 | EP0974664A2 Human polypeptides and polynucleotides homolog to mouse testes-specific angiotensins converting enzyme |
| 01/26/2000 | EP0974586A1 2-amino-4-alkylamino-pyrimidine 3-oxydes and compositions containing same |
| 01/26/2000 | EP0974362A1 Drugs containing enzyme inhibitors as the active ingredient |
| 01/26/2000 | EP0974361A1 Method of using antacid agent and pharmaceutical preparation containing antacid agent |
| 01/26/2000 | EP0973897A1 Human tumor-associated membrane protein |
| 01/26/2000 | EP0973894A1 Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use |
| 01/26/2000 | EP0973891A1 Human chemokine receptor-like chemokine |
| 01/26/2000 | EP0973819A1 Non-antigenic branched polymer conjugates |
| 01/26/2000 | EP0973818A1 Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same |
| 01/26/2000 | EP0973794A1 Netrin receptors |
| 01/26/2000 | EP0973731A1 Hydroxamic acid derivatives |
| 01/26/2000 | EP0973563A1 System, method and composition for dialysis and shock treatment |
| 01/26/2000 | EP0973551A2 Polymeric conjugates polyvalently presenting an agent for therapy |
| 01/26/2000 | EP0973534A1 Pharmaceutical compositions having appetite suppressant activity |
| 01/26/2000 | EP0973500A1 Use of sodium channel blocker in the manufacture of a medicament for preventing optic nerve degeneration associated with glaucoma |
| 01/26/2000 | EP0973461A1 Method of treatment of migraine |
| 01/26/2000 | EP0973396A1 A method of treating cancer |
| 01/26/2000 | EP0973392A1 Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 01/26/2000 | EP0763016B1 Compositions and methods for treating mast-cell mediated conditions |
| 01/26/2000 | EP0722316B1 New emulsion formulation |
| 01/26/2000 | CN1242802A Notch protein and their ligands |
| 01/26/2000 | CN1242703A Chewing gum contg. colloidal bismuth subcitrate |
| 01/26/2000 | CN1242237A Dietetic food composition and dietetic method using such composition |
| 01/25/2000 | US6017957 Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents |
| 01/25/2000 | US6017949 Controlling the fertility in a female mammal, terminating a pregnancy, controlling pathological conditions and disorders of the female reproductive system |
| 01/25/2000 | US6017932 Pharmaceutical compositions containing at least one NSAID having increased bioavailability |
| 01/25/2000 | US6017928 Retroviral protease inhibiting compounds |
| 01/25/2000 | US6017926 Integrin receptor antagonists |
| 01/25/2000 | US6017900 Topical composition containing hyaluronic acid and nsaids |
| 01/25/2000 | US6017885 IGF/IGFBP complex for promoting bone formation and for regulating bone remodeling |
| 01/25/2000 | US6017880 Inhibition of retrovirus infection |
| 01/25/2000 | US6017763 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 01/25/2000 | US6017728 ribH |
| 01/25/2000 | US6017544 Isolating stress protein-peptide complex from tumor cells previously removed from a mammal and administering the isolated stress protein-peptide complex along with a cytokine to the mammal in order to stimulate an immune response |